Analysts Set Definium Therapeutics, Inc. (NASDAQ:DFTX) Target Price at $35.22

Definium Therapeutics, Inc. (NASDAQ:DFTX) has been given an average recommendation of “Buy” by the twelve research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $35.2222.

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Definium Therapeutics in a report on Monday, February 2nd. Canaccord Genuity Group increased their price target on shares of Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Jones Trading started coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 target price for the company. Finally, Royal Bank Of Canada boosted their price target on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd.

Definium Therapeutics Trading Down 3.0%

NASDAQ DFTX opened at $15.75 on Friday. The firm has a market cap of $1.55 billion, a PE ratio of -7.72 and a beta of 2.57. Definium Therapeutics has a 1-year low of $4.70 and a 1-year high of $18.70. The stock has a 50-day moving average of $14.79 and a 200-day moving average of $12.36. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31.

Insider Transactions at Definium Therapeutics

In related news, insider Daniel Karlin sold 5,600 shares of Definium Therapeutics stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the sale, the insider owned 425,025 shares in the company, valued at $5,589,078.75. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 42,667 shares of company stock worth $561,071. 2.26% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Definium Therapeutics

A number of large investors have recently modified their holdings of the stock. Stoneridge Investment Partners LLC raised its stake in Definium Therapeutics by 7.5% in the third quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock worth $136,000 after buying an additional 804 shares in the last quarter. Cerity Partners LLC raised its position in shares of Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after acquiring an additional 1,165 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Definium Therapeutics by 9.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after purchasing an additional 1,400 shares during the period. Creative Planning lifted its stake in shares of Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the period. Finally, CWM LLC boosted its position in shares of Definium Therapeutics by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.